A High Response Rate to Liposomal Doxorubicin Is Seen Among Women With BRCA Mutations Treated for Recurrent Epithelial Ovarian Cancer
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2011.08.032
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2011
Authors
Publisher
Elsevier BV